January 10, 2013
Drs. Fred Poordad and. Eric Lawitz, liver specialists and professors at the University of Texas Health Science Center, evaluated a new drug combination to determine whether the hepatitis C virus could be cured quickly and without the adverse effects of current treatment using interferon. At present, standard treatment requires 48 weekly interferon injections to stimulate part of the immune system to fight the virus (but with the adverse effect of depressing other parts), combined with other drugs taken daily in pill form. According to Poordad, interferon causes many side effects, including flu-like symptoms, headaches, nausea, depression, and thyroid gland damage. As a result, some patients who have heard about interferons side effects do not get treated.
The researchers used two investigational drugs, ABT-450 and ABT-333, by Abbott Laboratories, which funded the study. Poordad explained that the investigational drugs are antiviral agents that stop the virus from replicating. For 12 weeks, the researchers treated 50 South Texas patients with pills containing the two investigational drugs and the currently used antiviral drug ribavirin and the drug ritonavir. The study reports that the new drug cocktail boosted the cure rate of certain patients from 70 percent to 95 percent in a quarter of the previous treatments time. Between 93 and 95 percent of patients who had not been treated previously were considered cured when evaluated after the treatment. Of the patients who had been unsuccessfully treated before, 47 percent were considered cured. The side effects of the new treatment were mild but included fatigue, nausea, headache, dizziness, insomnia, itching, rash, and vomiting.
The study, "Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C," was published in the New England Journal of Medicine (2013; 368:45-53).
San Antonio Express-News
01.08.2013; Jennifer R. Lloyd
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Expert: Long-Awaited CDC HIV Report on Conception Options for Serodiscordant Couples Is Disappointing and Confusing|
|This Week in HIV Research: Stable Housing Improves Viral Suppression and CD4 Counts|
|The Curious Case of M184V, Part 1|
|Inflammation in the Brain Continues Even With Undetectable Plasma Viral Load|
|Fat Gains Continue and Lean Mass Falls in Group on Long-Term HIV Therapy|
|The Best HIV Cure Will Be Built With Us, Not Just for Us|